## Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

L	ugai i iiiig		5 110 - 1 0111 4			
NEUROCRINE BIOSCIEN Form 4 May 22, 2014	CES INC					
FORM 4 UNITED				OMB APPROVAL		
UNITE	) STATES S	SECURITIES AND EXCHANGE Washington, D.C. 20549	E COMMISSION	OMB 3235-0287 Number:		
Section 16. Form 4 or		CHANGES IN BENEFICIAL O SECURITIES	Expires: January 31, 2005 Estimated average burden hours per response 0.5			
obligations may continue. See Instruction 1(b).	(a) of the P	ublic Utility Holding Company Act of 1	t of 1935 or Section	1		
(Print or Type Responses)						
1. Name and Address of Reportin MOLLICA JOSEPH A	2 [	2. Issuer Name <b>and</b> Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			X Director 10% Owner			
(Last) (First) PO BOX 1182	(	3. Date of Earliest Transaction (Month/Day/Year) 05/22/2014	X_ Director    10% Owner      Officer (give title    Other (specify below)			
(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
PRINCETON, NJ 08542			Person	ore than One Reporting		
(City) (State)	(Zip)	Table I - Non-Derivative Securities	Acquired, Disposed of,	, or Beneficially Owned		
1.Title of Security (Instr. 3)2. Transaction Dat (Month/Day/Year)	Execution D any		SecuritiesFeBeneficially(IOwned(IFollowing(IReportedTransaction(s)(Instr. 3 and 4)	Ownership7. Nature oform: DirectIndirectO or IndirectBeneficial)Ownershipnstr. 4)(Instr. 4)		
Reminder: Report on a separate li	te for each clas	ss of securities beneficially owned directly	or indirectly			
Reminder, Report on a separate in		Persons who re information con required to resp	spond to the collect tained in this form a ond unless the form ntly valid OMB cont	are not (9-02) n		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option $(1)$	\$ 12.98	05/22/2014		А		15,000		06/22/2014	05/22/2024	Common Stock	15,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
	Director	10% Owner	Officer	Other				
MOLLICA JOSEPH A								
PO BOX 1182	Х							
PRINCETON, NJ 08542								
Signatures								
Margaret E. Valeur-Jensen, By Attorney	2	05/22/2014						

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on June 22, 2014, an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.